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Abstract
Objective: Patients with severe left ventricular (LV) dysfunction have a poor long term survival
despite complete surgical revascularization. Recent data suggests that the use of Implantable
Cardioverter-Defibrillator (ICD) improves survival in patients with severe LV dysfunction. We
compared the survival impact of ICD implantation in patients with severe LV dysfunction who
underwent CABG.
Methods: Between January 1996 and August 2004, 305 patients with LV ejection fraction (EF)
≤25% had CABG surgery at our institution. Demographics of patients who had received an ICD
(ICD+) in the post -operative period was compared to those without ICD (ICD-). Survival was
evaluated by the Kaplan-Meier method.
Results: Of the entire group, 35 (11.5%) patients received an ICD with a median of 2 (+/-2) years
after CABG. Indication for ICD implantation was clinical evidence of non sustained ventricular
tachycardia (NSVT). There were no differences between the 2 groups with respect to age, gender,
NYHA classification, number of bypasses, or other co-morbidities. Survival at 1, 3 and 5 years was
88%, 79%, and 67% for the ICD- group compared to 94%, 89% and 83% for the ICD+ group,
respectively (figure, p < 0.05).
Conclusion: Implantation of ICD after CABG confers improved short and long term survival
benefit to patients with severe LV dysfunction. Prophylactic ICD implantation in the setting of
severe LV dysfunction and CABG surgery should be considered.
Background
Coronary artery bypass grafting in patients with severe left
ventricular dysfunction has been an accepted method of
treatment for revascularization [1,2]. Nonetheless, sud-
den cardiac death remains a significant cause of mortality
in patients who undergo coronary artery bypass grafting
with poor left ventricular function [3]. The use of implant-
able cardioverter-defibrillator (ICD) devices has been
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Insertion of an ICD has proved effective in decreasing the
incidence of sudden death in patients with poor left ven-
tricular function in general [4-7]. The CABG Patch trial
was a prospective randomized trial evaluating the prophy-
lactic implantation of ICD in patients with ejection frac-
tion (EF) < 36% who underwent CABG. They found no
evidence of improved survival among the group of
patients with coronary artery disease, depressed left ven-
tricular function and abnormal signal-average electrocar-
diogram in whom a defibrillator was implanted
prophylactically at the time of elective CABG [8]. The
CABG-Patch trial had selected patients on the basis of sig-
nal-averaged ECG, a marker that may not be as sensitive
for predicting sudden cardiac death in patients with severe
left ventricular dysfunction. The aim of this study was to
investigate the effect of ICD implantation on survival of
patients with EF ≤ 25% who underwent CABG, with no
previous criterion for selection, except perioperative
occurrence of ventricular tachyarrhythmias.
Methods
Between January 1996 and August 2004, 306 patients
were identified in our database that had isolated CABG
with a pre-operative EF ≤ 25%. The patients were divided
into two groups: patients who received an ICD (ICD+) in
the post-operative period and those without ICD (ICD-).
All patients were included in this analysis including emer-
gent and urgent operations. Only patients who had con-
comitant transmyocardial laser revascularization (TMR)
were excluded from this analysis. Determination of ejec-
tion fraction was based on preoperative left ventriculo-
gram, echocardiography, or a nuclear scan when
available.
Perioperative risk factors and demographics were deter-
mined from the database and supplemented by a detailed
chart review. Of the total of 305 patients, 35 received an
ICD (ICD+) and constitute the study group and the
remainder served as control. Mortality data was obtained
from chart review and supplemented from the United
States Social Security Death Index database. This study
was approved by the institutional review board of our
institution.
Statistical analysis
Data were analyzed using SYSTAT 11 (SYSTAT software
Inc., Point Richmond, CA) Continuous data are reported
as mean ± standard deviation (SD), and compared using
Student's t test. Categorical variables were analyzed using
the χ2 test or Fisher's exact tests as appropriate. Group dif-
ferences were also considered potentially significant at p <
0.05.
Variables with potential for significant difference between
the groups according to the univariate analysis were
entered as candidate variables in a multivariate stepwise
logistic regression analysis. For each element remaining in
the multivariate model, a parameter estimate was calcu-
lated from which a p value, odds ratios, and 95% confi-
dence interval for the variable were derived.
Actuarial survival rate curves were calculated according to
the Kaplan-Meier method and compared using the gener-
alized Wilcoxon test.
Results
Indication for ICD implantation was clinical evidence of
non sustained ventricular tachycardia (NSVT) in all 35
patients. Mean time for insertion of an ICD device from
time of operation was 2 years with a median of 1.2 years
and a range of 0 to 6.5 years. There were no differences
between the two groups based on age, gender, NYHA
functional classification, history of diabetes or other pre-
existing co-morbidities (Table 1). Ventricular tachyar-
rhythmias were slightly more prevalent in the ICD+ group
pre-operatively (23% vs. 11%) but this did not reach sta-
tistical significance (Table 2). Prevalence of other arrhyth-
mias was similar between the 2 groups with atrial
fibrillation dominating in the post-operative period
(Table 2).
Overall, approximately three-quarters of the patients in
each group had a previous history of myocardial infarc-
tion, and slightly over half of these patients had a MI
within 3 weeks of CABG surgery (Table 3). In all cases, all
appropriate targets were revascularized and more than
half of the patients had 3-vessel revascularization. There
was no difference between the 2 groups in terms of
number and type of grafts used (Table 3).
Follow up data for mortality was available for all 305
patients included in the study. The survival benefit for
patients with an ICD is illustrated in Figure 1. Survival at
1, 3 and 5 years was 88%, 79%, and 67% for the ICD-
group compared to 94%, 89% and 83% for the ICD+
group, respectively (p < 0.05).
Majority of the patients had their ICD inserted within 6
months of their CABG (Figure 2).
Discussion
CABG in patients with severe left ventricular dysfunction
can be performed with acceptable low operative risk [9-
11]. It is associated with good survival and improvement
in functional status and ventricular function [10]. Long-
term survival nonetheless is hampered with a high inci-
dence of sudden cardiac death [2,3]. Sudden cardiac death
(SCD) accounts for 300,000 deaths in the United States,Page 2 of 7
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deaths in the general population [12]. When observing a
sub-population that has an ejection fraction of < 30%, the
percentage rises dramatically and accounts for approxi-
mately 20% of all deaths [5-7]. The risk further increases
in patients with risk markers for arrhythmias and post-
myocardial infarction to approximately 35% [6,13]. The
absolute risk of SCD increases with deteriorating left ven-
tricular function and the ratio of sudden to non-sudden
deaths is inversely related to the extent of functional
impairment [14]. The proportion of sudden death that
have an important treatable arrhythmic component is
unclear, but trials of implantable defibrillators suggest
that this number can be as high as 50% [15,16].
In this retrospective review of patients with severe left ven-
tricular dysfunction, implantation of an ICD in the post-
operative period was shown to confer a survival advantage
in patients with clinical evidence of non-sustained ven-
tricular tachycardia after coronary bypass surgery. The sur-
vival data suggest that the beneficial effects of ICD
placement may become evident as early as one year post-
operatively. These results mirror what has been already
well established in multiple randomized trials.
The investigators of the MADIT I trial studied in a prospec-
tive randomized fashion the effect of ICD insertion on
patients with previous MI and LVEF < 35% with inducible
VT or history of nonsustained VT over medical therapy
alone [13]. MADIT II was a prospective randomized study
of the effect of ICD insertion on patients with previous MI
[5]. They used similar criteria as MADIT I, but without the
use of electrophysiologic studies to induce VT. The
MUSTT trial was another prospective randomized study
evaluating the effect of ICD insertion on patients with
LVEF < 40%, coronary artery disease, and history of unsus-
tained ventricular tachycardia with positive inducible ven-
tricular tachycardia [6]. In all 3 studies, ICD insertion
resulted in improved survival over conventional medical
therapy alone in patients with depressed left ventricular
function and coronary artery disease, regardless of the sta-
tus of revascularization.
In the majority of patients with significant left ventricular
dysfunction, it's conceivable that areas of potential
ischemic myocardium may remain despite complete sur-
gical revascularization. Many patients have small diseased
vessels that are not amenable to bypass surgery. In our
patients, over 70% of the patients who had ICD had a his-
tory of diabetes. In this difficult patient population, ina-
bility to completely revascularize every single area is the
rule rather than the exception. In addition, given the high
prevalence of previous myocardial infarctions in this
patient population, surgical revascularization cannot
Table 2: Incidence of all types of arrhythmias either pre-operatively or post-operatively.
Arrhythmia Type ICD+ ICD-
Pre-op Atrial 3 (8.57%) 42 (15.50%)
Heart Block 0 (0%) 12 (4.43%)
Ventricular 8 (22.85%) 30 (11.07%)
Combined 0 (0%) 14 (5.17%)
Post-op Atrial 9 (25.71%) 86 (31.73%)
Heart Block 0 (0%) 7 (2.58%)
Ventricular 1 (2.86%) 15 (5.54%)
Combined 0 (0%) 0 (0%)
Table 1: Patients demographics and co-morbidities.
ICD+ (N = 35) ICD- (N = 270)
Age 64.60 ± 10.06 66.60 ± 11.29
Gender Female 9 (25.71) 73 (27%)
Male 26 (74.29) 197 (73%)
EF 21.43 ± 4.30 21.35 ± 4.44
BMI 27.84 ± 5.05 27.80 ± 5.40
Smoking 27 (77.14%) 187 (69.26%)
Renal failure 5 (14.29%) 45 (16.61%)
Hypertension 25 (71.43%) 182 (67.16%)
Pulmonary hypertension 4 (11.43%) 62 (22.88%)
Angina 24 (68.57%) 210 (77.49%)
Diabetes 25 (71.43%) 133 (49.08%)
Peripheral vascular disease 4 (11.43%) 72 (26.67%)Page 3 of 7
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tion that patients with severe left ventricular dysfunction,
continue to have the substrate for ventricular tachyar-
rhythmias despite revascularization. These patients are at
risk for SCD from ventricular tachyarrhythmias and early
insertion of ICD should be strongly considered. Current
rules for reimbursement recommend a waiting period of
3 months after CABG prior to ICD implantation. Whether
these recommendations are prudent remains to be seen.
Unfortunately, most current thinking is based on the well-
designed prospective CABG Patch trial[4]. In this trial no
significant improvement of survival was observed with
insertion of ICD in patients with low ejection fraction
after CABG. The investigators used EF < 36% and abnor-
mal signal-averaged ECG as criteria for patient selection
and enrollment. Interestingly, despite no significant
reduction in overall mortality between the control group
and patients that received ICD, death due to cardiac
events was much lower in patients that received ICD post-
operatively [17].
Although a retrospective review such as our study has
many potential inherent weaknesses and should not be
compared to a rigorously performed prospective rand-
omized trial, in our opinion the question remains as to
why the CABG Patch trial did not show any significant
improvement in survival with ICD. Several plausible
explanations may exist.
ICD insertion after CABG in patients with severe left ventricular dysfuction improves survivalFigure 1
ICD insertion after CABG in patients with severe left ventricular dysfuction improves survival. The Kaplan-Meier Analysis of 
survival comparing the two group illustrates a significant improvement in survival in patients that received ICD post-operatively 
vs. patients that did not. Survival percentage is represented on the y-axis and time duration since CABG on the x-axis.
Table 3: Coronary pathology among all patients.
ICD+ N = 26 ICD- N = 228
MI Pre-op 26 (74.29%) 220 (81.18%)
Post-op 2 (5.71%) 2 (0.74%)
Duration of MI before CABG 6–24 hours 0 8 (3.51%)
1–7 days 9 (34.62%) 85 (37.28%)
8–21 days 6 (23.08%) 47 (20.61%)
> 21 days 11 (42.31%) 88 (38.60%)
Left main disease > 50% stenosis 8 (22.86%) 68 (25.19%)
Number of bypass grafts Single 5 (14.29%) 12 (4.44%)
Double 10 (29.57%) 65 (12.96%)
Triple 20 (57.14%) 193 (71.48%)Page 4 of 7
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ECG recordings have been used in risk stratification of
patients at risk for sudden cardiac death [18]. Signal-aver-
aged ECG's have been associated with a high negative pre-
dictive value and high sensitivity [19,20]. Nonetheless,
when observing a sub-population that underwent CABG,
signal-averaged ECG did not predict sudden cardiac death
[12].
In addition, ventricular late potentials have been recorded
in 70–90 percent of patients with spontaneous sustained
and inducible ventricular tachycardia after myocardial inf-
arction, in only 0–6 percent of normal volunteers, and in
7 to 15 percent of patients after myocardial infarction that
do not have ventricular tachycardia [12]. The presence of
these late potentials is a sensitive, but not specific, marker
of arrhythmic risk and thus its prognostic use is limited
[21]. More recently, Scharf and colleagues found no sig-
nificance in using signal-averaged ECG in predicting sud-
den cardiac death in patients that undergo CABG. In their
study, the only predictor appeared to be age and low ejec-
tion fraction [22].
Finally, the existence of more modern technology in man-
ufacturing of ICD devices may have been a reason for the
difference in results between our series and the results of
the CABG Patch trial. The fact that the newer generation
ICD devices are less implicated in malfunction as opposed
to older generations may have yielded improved results in
our series. Variability of device manufacturing may also
play a role in the altering the results of the CABG Patch
trial [23].
Our patient population included all patients with lower
ejection fraction than those enrolled in the CABG Patch
trial. Indication for ICD insertion was clinical evidence of
ventricular tachyarrhythmias. It is possible that many
patients who did not receive an ICD either experienced
SCD or had episodes of ventricular tachyarrhythmias that
were not manifested or recognized clinically. Unfortu-
Most patients with ICD's had insertion within the first year after the CABGFigure 2
Most patients with ICD's had insertion within the first year after the CABG. This graph illustrates the distribution of patients 
that received ICD post-operatively with respect to the date of their CABG. The y axis shows the percentage of patients in 
each group from the total patients that received ICD, the x axis shows the different groups. The groups represented were 
patients that had an ICD within six months of the CABG, from six months to two years, from two years to four years, from 
four years to six years and finally over six years from the time of their CABG.Page 5 of 7
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the patients reported herein. Nonetheless, with the inher-
ent limitations in this retrospective analysis, the survival
benefit of ICD in patients with severely dysfunctional ven-
tricles seems striking.
Conclusion
In conclusion, the results of this study suggest a reconsid-
eration of early ICD implantation in patients with severely
depressed left ventricular function that undergo CABG.
The question remains if another prospective trial in this
challenging patient population is warranted.
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